MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$63,174K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from sale of marketable...
Proceeds from revenue interest f...
Proceeds from borrowings, net of...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net loss
Contract liabilities
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2025-09-30
Net loss
-168,035
Stock-based compensation
27,906
Depreciation and amortization
1,200
Non-cash lease expense
281
Non-cash interest on revenue interest financing agreement
-5,121
Amortization of debt issuance costs
335
Change in fair value of warrant liability
-315
Amortization of premium on marketable securities
4,096
Realized (gain) loss on marketable securities
2
Net loss on disposal of fixed assets
-30
Unrealized foreign currency transaction loss
415
Acquired in-process research and development
0
Accounts receivable
-4,399
Prepaid expenses and other current assets
1,655
Inventory
5,710
Interest receivable on marketable securities
1,957
Other non-current assets
701
Accounts payable
9,012
Contract liabilities
8,838
Accrued expenses
-254
Net cash used in operating activities
-143,694
Cash acquired from anheart acquisition
0
Transaction costs related to anheart acquisition
0
Purchases of marketable securities
309,515
Proceeds from sale of marketable securities
330,217
Cash paid for capitalized market approval intangibles
8,000
Purchases of property and equipment
265
Net cash provided by investing activities
12,437
Proceeds from borrowings, net of debt issuance costs and debt discounts
48,901
Proceeds from revenue interest financing agreement
-150,000
Payments on borrowings
700
Payments of debt issuance costs
6,596
Payment on revenue interest financing agreement
68
Proceeds from issuance of common stock under espp
-533
Proceeds from exercises of options
2,402
Net cash provided by financing activities
194,472
Effect of foreign exchange rate changes on cash and cash equivalents
-41
Net increase (decrease) in cash and cash equivalents
63,174
Cash and cash equivalents at beginning of period
35,723
Cash and cash equivalents at end of period
98,897
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from revenue
interest financing...
-$150,000K
Proceeds from
borrowings, net of debt...
$48,901K
Proceeds from sale of
marketable securities
$330,217K
Proceeds from exercises
of options
$2,402K
Proceeds from issuance of
common stock under espp
-$533K
Net cash provided by
financing activities
$194,472K
Net cash provided by
investing activities
$12,437K
Canceled cashflow
$7,364K
Canceled cashflow
$317,780K
Net increase
(decrease) in cash and cash...
$63,174K
Canceled cashflow
$143,735K
Payments of debt issuance
costs
$6,596K
Payments on borrowings
$700K
Payment on revenue
interest financing...
$68K
Stock-based compensation
$27,906K
Accounts payable
$9,012K
Non-cash interest on
revenue interest...
-$5,121K
Accounts receivable
-$4,399K
Depreciation and
amortization
$1,200K
Amortization of debt issuance
costs
$335K
Non-cash lease expense
$281K
Net loss on disposal
of fixed assets
-$30K
Purchases of marketable
securities
$309,515K
Cash paid for
capitalized market approval...
$8,000K
Purchases of property and
equipment
$265K
Net cash used in
operating activities
-$143,694K
Effect of foreign
exchange rate changes on...
-$41K
Canceled cashflow
$48,284K
Net loss
-$168,035K
Contract liabilities
$8,838K
Inventory
$5,710K
Amortization of premium on
marketable securities
$4,096K
Interest receivable on
marketable securities
$1,957K
Prepaid expenses and
other current assets
$1,655K
Other non-current
assets
$701K
Unrealized foreign
currency transaction...
$415K
Change in fair value of
warrant liability
-$315K
Accrued expenses
-$254K
Realized (gain) loss on
marketable securities
$2K
Buy us a coffee
Nuvation Bio Inc. (NUVB-WT)
Nuvation Bio Inc. (NUVB-WT)